title
A Case of Dasatinib-Induced Hemorrhagic Colitis Diagnosed by the Lymphocyte Transformation Test in a Chronic Myeloid Leukemia Patient
A Phase I Dose Escalation Study Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in Patients with Chronic Hepatitis C
A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties
A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer
Acute renal failure under dasatinib therapy
Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase
Aged-senescent cells contribute to impaired heart regeneration
An unexpected and devastating adverse event of dasatinib: Rhabdomyolysis
Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials
Anti-ageing and rejuvenating effects of quercetin
Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis
Autophagy protects against dasatinib-induced hepatotoxicity via p38 signaling
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Bilateral subdural hemorrhage as a serious adverse event of dasatinib in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia
Bioavailability of quercetin: problems and promises
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy
Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells
Cardiac Tamponade Associated with Dasatinib Use for Chronic Myeloid Leukaemia
Cardiovascular Risk and Cardiovascular Events in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing
Cellular senescence drives age-dependent hepatic steatosis
Cellular senescence mediates fibrotic pulmonary disease
Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib
Chemical screen identifies a geroprotective role of quercetin in premature aging
Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review
Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice
Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies
Cytomegalovirus Colitis during Dasatinib Treatment for Patients with Hematologic Malignancy: Case Series and Literature Review
Cytomegalovirus-induced Hemorrhagic Colitis in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy
Cytotoxicity of flavonoids toward cultured normal human cells
Dasatinib
Dasatinib Induced Avascular Necrosis of Femoral Head in Adult Patient with Chronic Myeloid Leukemia
Dasatinib Induced Cardiac Tamponade-A Rare Association
Dasatinib Reinitiation After Poststroke Thrombolysis Associated with Symptomatic Intracerebral Hemorrhage
Dasatinib can Impair Left Ventricular Mechanical Function But May Lack Proarrhythmic Effect: A Proposal of Non-clinical Guidance for Predicting Clinical Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors
Dasatinib first-line: Multicentric Italian experience outside clinical trials
Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial
Dasatinib increases endothelial permeability leading to pleural effusion
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Dasatinib inhibits coated-platelet generation in patients with chronic myeloid leukemia
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
Dasatinib plus quercetin prevents uterine age-related dysfunction and fibrosis in mice
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
Dasatinib-Induced CMV Hepatitis in an Immunocompetent Patient: A Rare Complication of a Common Drug
Dasatinib-Induced Colitis in a Patient with Chronic Myelogenous Leukemia
Dasatinib-Induced Hypopigmentation in Pediatric Patient with Chronic Myeloid Leukemia: A Case Report and Review of the Literature
Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia
Dasatinib-Induced Pulmonary Arterial Hypertension
Dasatinib-Induced T-Cell-Mediated Colitis: A Case Report and Review of the Literature
Dasatinib-associated reversible demyelinating peripheral polyneuropathy in a case of chronic myeloid leukemia
Dasatinib-induced Seborrheic Dermatitis-like Eruption
Dasatinib-induced acute hepatitis
Dasatinib-induced chylothorax in chronic myeloid leukemia
Dasatinib-induced colitis: a case report
Dasatinib-induced haemorrhagic colitis in chronic myeloid leukaemia (CML) in blast crisis
Dasatinib-induced immune mediated-thrombotic thrombocytopenic purpura
Dasatinib-induced nephrotic-range proteinuria
Dasatinib-induced pleural effusion: Chylothorax, an option to consider
Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report
Dasatinib-related Follicular Hyperplasia: An Underrecognized Entity With Characteristic Morphology
Dasatinib-related chylothorax
Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature
Diffuse hypopigmentation followed by hyperpigmentation in an african american woman with hemangiopericytoma treated with dasatinib
Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure
Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension
Effects of senolytic drugs on human mesenchymal stromal cells
Efficacy and Safety of Generic Dasatinib as a Second-line Treatment for Patients with Chronic Myeloid Leukemia: a Multicenter Retrospective Study in Hubei Province, China
Elderly Patients With Chronic Myeloid Leukemia Benefit From a Dasatinib Dose as Low as 20 mg
Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios
Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na√Øve Chronic Myeloid Leukemia Patients Trial
Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety
Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: Case report
Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysis
Haemorrhagic colitis caused by dasatinib
Hair Depigmentation and Vitiligo-like Lesions in a Leukaemic Paediatric Patient during Chemotherapy with Dasatinib
Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor
Hematopoietic Stem Cell Transplant Survivors Study (HTSS Study) (HTSS)
Hyperoxia-induced Cellular Senescence in Fetal Airway Smooth Muscle Cells
Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics
Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience
Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia
Increased renal cellular senescence in murine high-fat diet: effect of the senolytic drug quercetin
Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
Investigation of quercetin and hyperoside as senolytics in adult human endothelial cells
Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study
Long-term results of frontline dasatinib in chronic myeloid leukemia
Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series
Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib
Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease
Obesity-Induced Cellular Senescence Drives Anxiety and Impairs Neurogenesis
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer
Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case
Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study
Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors
Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors
Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series
Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment
Pulmonary arterial hypertension in a patient treated with dasatinib: a case report
Quercetin Enhances Ligand-induced Apoptosis in Senescent Idiopathic Pulmonary Fibrosis Fibroblasts and Reduces Lung Fibrosis In Vivo
Quercetin pharmacokinetics in humans
Quercetin, an over-the-counter supplement, causes neuroblastoma-like elevation of plasma homovanillic acid
Quercetin-3-O-Œ≤-D-glucuronide isolated from Polygonum aviculare inhibits cellular senescence in human primary cells
Quercetin-induced apoptosis ameliorates vascular smooth muscle cell senescence through AMP-activated protein kinase signaling pathway
Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease
Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib
Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment
Restoring Effects of Natural Anti-Oxidant Quercetin on Cellular Senescent Human Dermal Fibroblasts
Reversible skin and hair depigmentation during chemotherapy with dasatinib for chronic myeloid leukemia
Reversible ventricular arrythmia induced by dasatinib
Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis
SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma
Safety Aspects of the Use of Quercetin as a Dietary Supplement
Senescence in Chronic Kidney Disease
Senolytic Cocktail Dasatinib+Quercetin (D+Q) Does Not Enhance the Efficacy of Senescence-Inducing Chemotherapy in Liver Cancer
Senolytic Therapy to Modulate Progression of Alzheimer's Disease (SToMP-AD)
Senolytic therapy alleviates AŒ≤-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer's disease model
Senolytics (DQ) Mitigates Radiation Ulcers by Removing Senescent Cells
Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease
Senolytics improve physical function and increase lifespan in old age
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
Severe agitation in depression precipitated by dasatinib
Severe thrombocytopenia after dasatinib treatment in a patient with Philadelphia chromosome-positive chronic myeloid leukemia
Short-term High Dose of Quercetin and Resveratrol Alters Aging Markers in Human Kidney Cells
Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report
Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment
Targeted Reduction of Senescent Cell Burden Alleviates Focal Radiotherapy-Related Bone Loss
Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial (IPF)
Targeting cellular senescence prevents age-related bone loss in mice
Targeting senescence improves angiogenic potential of adipose-derived mesenchymal stem cells in patients with preeclampsia
Targeting senescent cells alleviates obesity-induced metabolic dysfunction
Tau protein aggregation is associated with cellular senescence in the brain
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
The Cancer Drug Dasatinib Increases PGC-1Œ± in Adipose Tissue but Has Adverse Effects on Glucose Tolerance in Obese Mice
The antioxidant, rather than prooxidant, activities of quercetin on normal cells: quercetin protects mouse thymocytes from glucose oxidase-mediated apoptosis
The impact of dasatinib on pregnancy outcomes
The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia
The murine dialysis fistula model exhibits a senescence phenotype: pathobiological mechanisms and therapeutic potential
The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo
Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects
[Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia]
[Inflammatory reactive polyposis caused by dasatinib:a case report]
[Study on efficiency and safety of dasatinib in Chinese patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib]
